Comparative study on MRI Versus X-Ray in detecting Bone Metastasis in Patients with Locally Advanced Breast Carcinoma by Govindaraj, D
COMPARATIVE STUDY ON MRI versus                   
X-RAY IN DETECTING BONE METASTASIS 
IN PATIENTS WITH LOCALLY ADVANCED 
BREAST CARCINOMA 
 
 
M.S DEGREE EXAMINATION 
BRANCH I - GENERAL SURGERY 
 
Department of General Surgery 
MADURAI MEDICAL COLLEGE AND GOVT RAJAJI HOSPITAL 
Madurai – 20 
APRIL 2019 
 
 
 
 
 
 
 
 
 
 
 
THE TAMILNADU DR.M.G.R.MEDICAL UNIVERSITY 
CHENNAI, TAMILNADU, INDIA. 
 
 
BONAFIDE CERTIFICATE 
This is to certify that the dissertation entitled “Prospective 
study comparing the effectiveness of CT and MRI spine in 
detecting occult spine metastasis in patients with locally 
advanced breast carcinoma” submitted by Dr.D.Govindaraj to 
the Tamilnadu Dr.M.G.R medical university, Chennai in partial 
fulfillment of the requirement for the award of M.S Degree 
Branch 1 (General Surgery), is a bonafide research work carried 
out by him under my supervision & guidance. 
 
 
Prof.Dr.SR.Dhamodaran MS., 
Professor and Head 
Department of General Surgery 
Madurai Medical College, Madurai-20. 
PLACE : Madurai 
DATE :  
CERTIFICATE BY THE DEAN 
This is to certify that the dissertation entitled “Prospective 
study comparing the effectiveness of CT and MRI spine in 
detecting occult spine metastasis in patients with locally 
advanced breast carcinoma” is a bonafide research work done 
by Dr.D.Govindaraj., Post graduate student, department of 
general surgery, Madurai Medical College, Madurai, under 
guidance and supervision of Prof.Dr.D.Marudhupandian 
MS.,FICS.,FAIS., unit chief, department of general surgery, 
Madurai Medical College, Madurai. 
 
 
Dr.D.Marudhupandian MS., FICS.,FAIS., 
DEAN 
       MADURAI MEDICAL COLLEGE, 
MADURAI  
PLACE: MADURAI 
DATE: 
 
 
 
DECLARATION 
I, Dr.D.GOVINDARAJ declare that, I carried out this 
work on “Prospective study comparing the effectiveness of CT 
and MRI spine in detecting occult spine metastasis in patients 
with locally advanced breast carcinoma” at the department of 
general surgery, Govt.Rajaji hospital Madurai, during the period 
of Jan2018 to April2019. I also declare that this bonafide work or 
a part of this work was not submitted by me or any others for any 
award, degree and diploma to any other university, Board either 
in India or abroad. 
This is submitted to The Tamil Nadu Dr.M.G.R Medical 
University, Chennai Chennai in partial fulfillment of  the rules 
and regulations for the M.S Degree examination in general 
surgery.  
 
 
PLACE:           Dr.D.GOVINDARAJ 
DATE:   
ACKNOWLEDGEMENT 
 
I wish to thank our DEAN Dr.D.Marudhupandian MS., 
FICS.,FAIS., for permitting to use the facilities of Madurai 
medical College and government Rajaji Hospital to conduct the 
study. 
I thank sincerely, Prof.Dr.D.Marudhupandian MS., 
FICS., FAIS.,  my unit chief and dean for his valuable advice and 
co-operation in completing the study. He has always guided 
me  by example and valuable words of advice and has given me 
his moral support. I will be grateful to him forever. 
I offer my heartfelt thanks to my unit assistant professors 
Dr.D.LATHA MS.,DA., Dr.C.SARAVANAN MS., D.Ortho., 
Dr.S.THIRUMALAIKANNAN MS., DCh., Dr.S.MUTHU 
KUMAR MCh, Dr.C.RAJ KUMAR MCh., for their constant 
encouragement timely help critical suggestions throughout the 
study and also for making My stay in the unit both informative 
and pleasurable 
My patients, who form the most integral part of the work, 
were always kind and cooperative. I pray God to give them 
courage and strength to endure the release hope all of them go 
into complete remission. 
 
 
             Dr.D.GOVINDARAJ 
  
LIST OF ABBREVIATIONS 
 
LABC locally advanced breast carcinoma 
MRI  magnetic resonance imaging 
CT  computed tomography 
PET  positron emission tomography 
SPECT single photon emission computed tomography 
STIR Short tau inversion recovery 
FLAIR Fluid-attenuated inversion recovery 
DM  diabetes mellitus 
SS  skeletal scintigraphy 
  
TABLE OF CONTENTS 
 
SL.NO CONTENTS PAGE 
NO 
1 INTRODUCTION 1 
2 REVIEW OF LITERATURE 2 
3 RESEARCH PROPOSAL 58 
4 OBSERVATION AND RESULTS 66 
5 DISCUSSION 77 
6 CONCLUSION 78 
7 REFERENCES 79 
8 MASTER CHART 84 
9 
ETHICAL COMMITTEE 
CERTIFICATE  
88 
10 DIGITAL RECIEPT 89 
 
1 
 
INTRODUCTION 
Carcinoma breast is the second most common mortality 
causing cancer next to pulmonary carcinoma worldwide. In India, 
more than one million women are detected with breast cancer 
every year. Due to robust healthcare detection of breast cancer, 
there is a shift in focus from detection of breast cancer, towards 
appropriate management of breast cancer of all stages. Hence, we 
studied the need for early detection of spine metastasis which is 
the most common bone spread of breast cancer, by comparing the 
accuracies of CT Scan and MRI of spine.  
By this, a patient with LABC is detected with spine 
metastasis, the patient is considered as stage 4 which changes the 
management protocol. 
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REVIEW OF LITERATURE 
PROSPECTIVE STUDY COMPARING THE ROLE OF CT 
SPINE AND MRI SPINE IN DETECTING OCCULT SPINE 
METASTASIS IN PATIENTS WITH LOCALLY ADVANCED 
BREAST CARCINOMA 
 
ANATOMY OF THE BREAST 
  The breast develops at 5-6 weeks of intrauterine life from 
two ventral bands of thickened ectoderm called the mammary 
ridges. The breast is rudimentary in males. In females the breast 
starts developing just before puberty.  
The mammary gland or the breast lies over the Anterior 
chest wall otherwise called the pectoral region. Though the 
breasts are rudimentary in males it forms an important 
reproductive organ in the females.  
  The breast lies in the superficial fascia of the pectoral 
region. It is divided into four quadrants called upper medial, 
upper lateral, lower medial, lower lateral. There is a small 
extension of the breast called the axillary  tail of Spence.  
3 
 
The breast is located between 2 to 6 ribs vertically and from 
the lateral border of the sternum to the mid axillary line. The 
Breast is separated from the pectoral fascia by the retromammary 
space.  
The nipple is present at the level of the fourth intercostal 
space. Many circular and longitudinal muscle fibers make up the 
nipple. The nipple contains many sweat and sebaceous glands. 
The circular area around the nipple is called the areola. The areola 
also contain sebaceous glands. 
 
Fig: Anatomical location of breast 
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The breast is a compound tubulo alveolar gland which 
secretes milk. There are 15 to 20 lobules. Each lobules contain 
alveoli in clusters. The lactiferous ducts converge near the nipple 
into a dilatation called the lactiferous sinus.  
Blood supply. 
Internal thoracic artery 
Axillary artery throught the lateral thoracic, superior thoracic and 
acromiothoracic arteries. 
Posterior intercostal artery.  The Veins Follow the arteries. 
NERVE SUPPLY 
The 4-6 intercostal nerves supply the breast. These nerve 
fibres supply only the sensory and autonomic sensations. The 
milk secretion is governed by the pituitary and the hypothalamus.  
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Fig: blood supply of the breast 
 
Fig: Neuroendocrine control of the breast 
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LYMPHATIC DRAINAGE:  
1. Axillary lymphnodes, grouped into central, posterior, 
lateral, apical. 
2. The internal mammary nodes 
3. Supraclavicular nodes 
4. Cephalic (deltopectoral nodes) 
5. Posterior intercostal nodes. 
The lymphatic drainage is very important as it forms the 
platform for spread of carcinoma cells from the breast to all over 
the body. 
The lymph channels have no valves. Most lymph is drained by 
the axillary nodes. 
The left breast drain into the thoracic duct and the right breast 
drain into the right subclavian vein. Rotters nodes are 
interpectoral nodes.  
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Fig: lymphatic drainage of breast 
 
The axillary vein group, called the lateral group, consists 
of four to six lymph nodes that lie lateral and posterior to the 
axillary vein. This group is well identified at the anatomic 
confluence of the lateral vein with the latissimus dorsi. These 
nodes receive the majority of lymphatic contents from the upper 
extremity and ipsilateral back with the exception of lymph that 
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drains into the deltopectoral lymph nodes, a group also referred 
to as the infraclavicular nodes. 
  The external mammary group, called the anterior or 
pectoral group, consists of four or five lymph nodes positioned 
along the lower and lateral border of the pectoralis minor muscle 
contiguous in association with the lateral thoracic vessels. These 
nodes receive the principal volume of lymph drainage from the 
breast parenchyma. From these nodes, lymph drains primarily 
into the central lymph nodes. However, lymph may pass directly 
from the external mammary nodes to the subclavicular lymph 
nodes. 
The central group, centrally positioned, consists of three to 
four large lymph nodes that are embedded in the fat of the axilla, 
usually behind the pectoralis minor muscle. These nodes receive 
lymph from the preceding nodal groups (axillary, external 
mammary, and scapular nodal sites) and may also receive afferent 
lymphatic vessels directly from the breast. Lymph from the 
central group, which may lie directly upon the ventral and anterior 
aspects of the axillary vein, drains directly to the subclavicular 
9 
 
(apical, level III) nodes. This group is often placed superficially 
beneath the skin and the fascia of the midaxilla, and it is centrally 
located between the posterior and anterior axillary folds. This 
nodal group is the most palpable and numerous of axillary 
lymphatics, and because of its superficial position may provide 
accurate clinical assessment of metastatic disease. 
The interpectoral or Rotter group consists of one to four 
small lymph nodes located between the pectoralis major and 
minor muscles. This group is bordering with pectoral branches of 
the thoracoacromial vessels. Lymph from these nodes enters the 
central and subclavicular nodes 
The subclavicular group, called the apical group, consists 
of 6 to 12 lymph nodes that are located in part posterior and 
partially above the upper border of the pectoralis minor muscle. 
This nodal group extends into the apex of the axilla along the 
medial aspect of the axillary vein. These nodes receive lymph 
from all the other axillary lymph node groups. Thereafter, these 
efferent lymphatic vessels from the subclavicular lymph nodes 
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unite to form the subclavian trunk. The course of the subclavian 
trunk is highly variable anatomically. 
It may join and directly enter the internal jugular vein or the 
subclavian vein, or their junction. On the right side of the 
subclavian trunk, the right lymphatic duct may enter this 
structure, whereas on the left side confluence with the thoracic 
duct is common. Efferent vessels from the subclavicular lymph 
nodes may also pass to the deep cervical lymph nodes. 
Axillary lymphatics are divided according to their lateral 
and medial (surgical) anatomic relationships with the pectoralis 
minor muscle into three distinct levels and are identified as levels 
I through III. Level I nodes are located lateral to or below the 
inferior border of the pectoralis minor; this level includes the 
external mammary, the lateral axillary vein, and the scapular 
lymph node groups. Level II nodes are located deep in or behind 
the pectoralis minor and include the central lymph node group 
and possibly some of the subclavicular lymph node group.  
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Level III nodes are located superomedial to the upper 
margin of the pectoralis minor and include the subclavicular 
(apical) lymph node group. 
 
Fig: Lymphatic drainage of upper limb and breast 
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ABERRATIONS OF NORMAL DEVELOPMENT & 
INVOLUTION 
 
 
Fig: Aberrations of normal development and involution (ANDI) 
ANDI classifies benign breast disorders which may be normal 
processes in reproductive life and to involution, diseases of the 
breast and pathogenesis and degree of abnormality  
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Table: Cance Table: Cancer risk associated with various 
breast disorders and diseases. 
Abnormality Relative risk (RR) 
Non proliferating lesions No risk 
Sclerosing adenosis No risk 
Intraductal papilloma No risk 
Florid hyperplasia 1.5-2.0 
Atypical lobular hyperplasia 4 
Atypical ductal hyperplasia 4 
Lobular carcinoma in situ 10 
Ductal carcinoma in situ 10 
 
RISK FACTORS FOR BREAST CANCER 
NON MODIFIABLE: 
 Age 
 Female sex 
 Early menarche 
 Late menopause 
 Nulliparity 
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 Family history 
 Genetic risk 
 Personal history of cancer 
 Race & ethnicity 
 Radiation exposure 
 
MODIFIABLE: 
 Age at first child birth 
 Parity 
 Breast feeding 
 Obesity 
 Alcohol and tobacco consumption 
 Hormone replacement therapy 
 Physical activity 
HISTOLOGICAL RISK FACTORS: 
 Proliferative breast disease 
 Atypical ductal hyperplasia 
 Atypical lobular hyperplasia 
 Lobular carcinoma in situ 
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FIG: classification of primary breast carcinoma 
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STAGING OF BREAST CANCER 
 
 
 
 
 
 
STAGE DESCRIPTION 
Tis Carcinoma In Situ 
T1 Tumour <2cm in greatest dimension 
T2 Tumour 2-5cm in greatest dimension 
T3 Tumour >5cm in greatest dimension 
T4A Extension to the chest wall not including pectoralis 
muscle invasion 
T4B Ulceration/ipsilateral satellite nodule/edema 
including peau d’orange which do not meet criteria 
for inflammatory carcinoma 
T4C Both T4a and T4b 
T4D Inflammatory carcinoma 
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M STAGE DESCRIPTION 
MX Metastasis  could not be assessed 
M0 No evidence of metastasis 
M1 Clinical/radiological evidence of metastasis 
  
N STAGE DESCRIPTION 
N0 No regional nodes 
N1 Metastasis to ipsilateral mobile level 1,2 axillary 
nodes 
N2A Metastasis to ipsilateral matted level 1,2 axillary 
nodes 
N2B Metastasis to ipsilateral internal mammary nodes 
in the absence of axillary lymphnodes 
N3A Metastasis in ipsilateral infraclavicular nodes 
N3B Metastasis in ipsilateral axillary and internal 
mammary nodes 
N3C Metastasis in ipasilateral supraclavicular nodes 
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TABLE: TNM GROUP STAGING 
The stages highlighted constitute LABC (locally advanced 
breast carcinoma) 
 
STAGE 0 T0 N0 M0 
STAGE 1A T1 N0 M0 
STAGE 1B T0 N1mi M0 
 T1 N1mi M0 
STAGE 2A T0 N1 M0 
 T1 N1 M0 
 T2 N0 M0 
STAGE 2B T2 N1 M0 
 T3 N0 M0 
STAGE 3A T0 N2 M0 
 T1 N2 M0 
 T2 N2 M0 
 T3 N1 M0 
 T3 N2 M0 
STAGE 3B T4 N0 M0 
 T4 N1 M0 
 T4 N2 M0 
STAGE 3C ANY T N3 M0 
STAGE 4 ANY T ANY N M1 
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DIAGNOSTIC STUDIES FOR BREAST CARCINOMA 
PATIENTS 
INVESTIGATION Stage 
0 
Stage 
1 
Stage 
2 
Stage 
3 
Stage4 
History & physical * * * * * 
Blood 
investigations 
 * * * * 
X-ray   * * * 
Mammogram * * * * * 
Hormone receptor 
study 
* * * * * 
HER-2/neu  * * * * 
Bone scan    * * 
Ultrasound 
abdomen 
   * * 
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MANAGEMENT  
EARLY BREAST CANCER 
 Surgery-Lumpectomy 
 Radiotherapy 
 Axillary node management(SLND/ALND) 
 Chemotherapy 
 Hormonal therapy 
 Immunomodulators 
 
Disease free survival is equivalent to mastectomy if patient is 
carefully selected. Even though sounds simple, BCS is more 
complicated than MRM. 
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LOCALLY ADVANCED BREAST CANCER: 
 
Fig: Locally Adnvanced Breast Cancer 
Tumour: 
T3:    Lump >5cm 
T4a : Extension to chest wall 
T4b : Skin involvement 
T4c : T4(a+b)  
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T4d : Inflammatory Carcinoma 
 
Nodal status: 
 N2a : Ipsilateral Fixed/ matted axillary nodes 
 N2b : Ipsilateral Internal Mammary Nodes 
              (Axillary Node negative) 
 N3a : Ipsilateral Infraclavicular  
 N3b : N2(a+b) 
 N3c : Ipsilateral Supraclavicular nodes 
Metastasis  
         M0 
CLINICAL PRESENTATION: 
Lump >5cm 
Grave Signs: 
 Skin Edema 
 Skin ulceration 
 Chest wall Fixity 
 >2.5cm Axillary Node 
 Fixed Axillary node 
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 Satellite skin nodules 
 Infraclavicular, Internal Mammary, Supraclavicular nodes 
INVESTIGATIONS: (as necessary) 
 Mammography 
 Trucut biopsy 
 CT chest and abdomen 
 Skeletal survey 
 MRI scan 
 PET CT 
 
24 
 
 
 
Table 1&2: Treatment pathways for LABC 
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MANAGEMENT: 
 Surgery  
 Chemo therapy 
 Radio therapy 
 Hormonal therapy 
 Monoclonal antibodies 
Women presenting with stage IIIa and IIIb breast cancer 
have advanced locoregional breast cancer but have no 
clinically detected distant metastases. In an effort to provide 
optimal loco regional control as well as distant disease control 
for these women, surgery is integrated with radiation therapy 
and chemotherapy. Stage IIIa patients are divided into those 
who have operable disease and those who have inoperable 
disease. Surgical therapy for women with operable stage IIIa 
disease is usually a modified RM, followed by adjuvant 
chemotherapy, followed by adjuvant radiation therapy. 
Adjuvant chemotherapy is used to maximize distant disease-
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free survival, while radiation therapy is used to control 
locoregional disease. 
In selected stage IIIa patients, initial (neoadjuvant) 
chemotherapy is used to reduce the size of the primary cancer and 
permit conservation surgery. For inoperable stage IIIa and for 
stage IIIb breast cancer, neoadjuvant chemotherapy is used to 
decrease the loco regional cancer burden and can permit 
subsequent surgery to establish loco regional control. In this 
setting, a modified Radical Mastectomy followed by adjuvant 
chemotherapy and adjuvant radiation therapy 
STAGE 4 DISEASE: 
Metastatic breast carcinoma includes any T, any N with 
metastasis to contralateral breast, axilla, supraclavicular region, 
skeletal and soft tissue metastasis, visceral metastasis. Patients 
present with various presentations which may include bone pain, 
neurological weakness, bladder& bowel dysfunction, rectal 
deposits causing hematochezia, loss of consciousness, dyspnoea 
and chest pain. 
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Fig: management outline for metastatic disease 
 
The 5 year survival rates for stage 4 disease is around  22% 
among which TRIPLE NEGATIVE disease is more likely to recur 
and present with metastasis  in first 5 year. Skeletal tissue 
metastasis have better prognosis. 
TREATMENT OBJECTIVES: 
B reast cancer has excellent prognosis provided detected at an 
appropriate time and managed. Hence it becomes imminent to 
accurately identify and stage the disease. The management of 
CA. BREAST
METASTATIC 
LESION
HORMONAL,
CHEMOTHERAPY
RT
PRIMARY ?SURGERY
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metastatic disease aims at Control of tumor burden, Reduction in 
cancer related symptoms or complications, Maintenance of quality 
of life & function. 
BONE METASTASIS: 
Isolated bone metastasis due to breast carcinoma has an 
excellent survival rate of 39% at 5 years. 
The skeletal metastasis may occur at: 
 Spine 
 Pelvis 
  Femur 
 Humerus  
  Ribs 
  Skull 
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FIG: Types of bone metastasis, bone structure and 
appearance in various investigations. 
SPINE METASTASIS: 
The deposition of tumour cells in the spine occurs by the 
blood stream especially through the venous plexuses which are in 
continuity with the spinal plexuses called the Batson’s plexus. 
These are low pressure venous plexuses in communication with 
the vertebra and the pelvis via azygos veins.  Tumour seedling 
occurs even with increased abdominal pressures like coughing 
and straining. The incidence of vertebral depositions of tumour 
cells is as high as 84% and is the most common site of deposits 
in carcinoma breast. Among the spine, thoraco dorsal spine or 
dorsolumbar spine is the most common site followed by cervical 
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spine and the pelvis. As soon as the tumour seedling occurs the 
abundant growth factors present in the spinal columns initiate 
further events leading to widespread vertebral metastasis. The 
percentage of patients affected with occult spine metastasis are 
2% in stage 1, 6-10% in stage 2, and 16-20% in stage 3 and upto 
40% in metastatic disease.  
The various presentations of  spine metastasis that can occur 
due to breast carcinoma are, 
1. Isolated low  back pain of recent onset 
2. Epidural spinal cord compression (ESCC) 
3. Radiculopathy 
4. Brachial plexopathy 
5. Myelopathy  
Isolated low back pain: 
This is the most common symptoms presentation in early 
metastasis which is recent in onset . patient should be highly 
suspected for spine metastasis and should be well evaluated. Plain 
X-Ray of  axial skeleton should be done. A CT spine can 
demonstrate bony lesions. However an MRI can delineate soft 
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tissues better than CT and hence should be employed wherever 
possible.  
1. Epidural spinal cord compression (ESCC) 
The tumour cells via the bloodstream gets deposited in the 
spinal epidural space triggering a neurological emergency. The 
symptoms commonly present is only back pain of recent onset 
usually 7 days or more. The identifications of such patients is 
important to prevent further neurological damage or slow down 
the progression if not reversible. The epidural spinal compression 
in breast cancer usually follows vertebral metastasis and rarely 
occurs directly. Hence identification of vertebral metastasis at an 
early stage can prevent further damage with prompt treatment.  
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Fig: Sagittal CT scan demonstrating lytic destruction of the 
T12 vertebral body due to a breast metastasis  
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Fig: T2-weighted sagittal MRI demonstrating the T12 breast 
metastasis and the severe spinal cord compression. The spinal 
fluid appears white on this sequence. The tapering of the 
spinal fluid on the sagittal image in the region of the mass is 
characteristic of compression from an extradural mass 
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Most common symptoms and presentation of epidural 
compression 
Symptoms  Description  
Back pain 95% 
Weakness 35-75% 
Inability to walk 50-68% 
Sensory deficit 50-70% 
Autonomic disturbance 50-60% 
 
2. RADICULOPATHY: 
Radiculopathy when present indicates a possible metastasis 
in the spine in the range of 44-63%. An abnormal X-Ray of spine 
with radiculopathy symptoms in indicative of almost 90% chance 
of metastasis.  
3. PLEXOPATHY: 
Brachial plexus lesions present with pain and weakness of 
upper limbs. On futher progression, the lower limbs are also 
affected. Horner’s syndrome strongly indicates brachial 
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plexopathy. The other symptoms are lymphedema and 
parasthesias.  
4. MYELOPATHY: 
Autonomic And Sensory Disturbance Like Bowel, Bladder 
Dysfunction Point Towards Myelopathy.  
 
MANAGEMENT: 
 
 
 
 
Bone 
metastasis 
Radiotherapy Chemotherapy Surgery
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Medical management of bone metastasis includes 
bisphosphanates therapy. Zoledronic acid (bisphosphanates), 
denosumab and lapatinib are used where the latter two are 
monoclonal antibodies.  
Patients presenting with bone pain are subjected to 
radiotherapy provided there is no cord compression. Patients 
presenting with cord compression symptoms as described later 
are subjected to radiotherapy and steroids. 
Patients at risk of fracture are planned for elective 
prophylactic stabilization and patients presenting with fractures 
require fracture fixation as an emergency to prevent neurological 
damage.  
 
IMAGING IN BONE METASTASIS: 
The marrow of the vertebrae undergoes constant 
remodeling and therefore the bone lesions in breast carcinoma can 
occur as bone destruction (osteolytic), new bone forming changes 
(osteoblastic) and mixed types. 
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THE SEED AND SOIL HYPOTHESIS: 
The bone environment represents a “fertile soil” in which 
some, but not all, cancer cell types (seeds) can flourish. This was 
proposed by STEPHEN PAGET in 19th century. 
Most deposits from breast carcinoma induces osteolytic 
changes in the vertebrae by activation of osteoclasts indirectly by  
multiple factors. Indirect stimulation is mediated by up-regulation 
of RANK-RANKL signaling, either by osteoblast-mediated 
osteoclastogenesis or via stimulation of host immune cells by 
factors such as PTHrP. In addition, bone breakdown releases 
previously deposited growth factors and cytokines within the 
matrix. This has a proliferative effect on the metastatic cells, thus 
creating a vicious sequence of bone resorption. 
The osteoblastic component has  three mechanisms. 
1. The tumor cells influences other cells like stromal cells  in 
its microenvironment which differentiates into osteoblasts. 
2. Metastatic cells secrete factors which directly stimulate 
osteoblast production and bone formation. 
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3. The natural local bone response to increased bone 
destruction.   
Thus the resultant lesion is variable, causing the degree of 
overall bone distortion by the infiltrating metastatic tumor. 
IMAGING MODALITIES: 
1. X-ray plain  
2. CT plain 
3. MRI  
4. SKELETAL SCINTIGRAPHY(SS) 
5. PET-CT 
6. SPECT 
There are various imaging modalities available to detect 
vertebral metastasis but multiple factors like sensitivity, 
specificity, availability, feasibility, cost effectiveness has to be 
considered before selecting an appropriate investigation for 
patients especially in developing nations like India. 
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IMAGING 
MODALITY 
SENSITIVITY(%) SPECIFICITY(%) 
18 NaF-PET/CT 100 97 
MRI 95 90 
SPECT 87 91 
CT 74 56 
BONE 
SCINTIGRAPHY 
78 48 
X-RAY 60 50 
 
 
X-Ray spine:  
Plain x-rays are the first investigations done to detect 
vertebral abnormalities and to stratify the risk of pathological 
fractures in patients with symptoms. However, plains x-rays are 
low in sensitivity and specificity to detect and delineate occult 
metastasis of the spine. Less contrast between trabecular and 
cortical bone makes this detection difficult by plain x-rays.  
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ADVANTAGES OF X-RAY SPINE: 
 Ready availability 
 Low cost 
 Useful for mass screening 
 
DISADVANTAGES OF X-RAY SPINE: 
 Low sensitivity – atleast 50-70% bone lysis should occur to 
be detected by X-Ray which converts into 3-6months period 
after symptoms. 
 Low specificity  
 Do not provide soft tissue metastatic deposit status 
Therefore a normal x-ray film doesn’t rule out a metastatic 
deposit triggering a further look out for additional 
modalities.  
 
CT SPINE: 
CT scan is excellent for cortical destruction which 
delineates the anatomy well compared to x-ray. CT requires very 
less period from onset of symptoms to detection of vertebral lytic 
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lesions but is poor in detecting marrow and soft tissue lesions 
which occur well ahead of bone destruction. The sensitivity is 
74% and it is 56% specific.  
 
ADVANTAGES OF CT: 
 Manipulate bone specific image techniques to acquire 
images which increases sensitivity (window width and 
level, multiplanar imaging). 
 Can be used for staging simultaneously  
 Quick to perform 
 Low cost 
 Easy availability 
 
DISADVANTAGES: 
 Low sensitivity and specifity comparatively. 
 Radiation exposure 
 Inability to detect soft tissue lesions 
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MRI SPINE: 
MRI has an excellent soft tissue resolution. The signal intensity 
variations can detect tumour cells in the bone marrow which is 
ahead of cortical bone destruction. Hence MRI is a very useful 
investigation modality to detect spine metastasis at an early stage.  
DETECTED BY 
MRI 
 
DETECTED BY 
SCINTIGRAPHY 
 
DETECTED BY CT/ 
PLAIN  X-RAY 
 
 
The sensitivity and specificity for MRI are 95% and 90% 
respectively. 
MRI technology has evolved dramatically in recent years 
with excellent techniques to acquire whole body images with 
reduced scanning times. 
Tumour seedling in marrow
Tumour activity in bone
Destruction of bone
43 
 
CONCEPT OF MRI IN SPINE METASTASIS: 
MRI has certain specific signal intensity variations to detect 
marrow tumour cell seedling though these are common for other 
bone metastasis also. 
Fat demonstrates high signal intensity in T1 weighted 
images. As the normal marrow contains high fat content there is 
hyperintensity in T1W images in a normal patient whereas a 
metastatic deposit may cause low intensity (hypointensity) 
signals in T1 Weighted images due to replacement of fat by the 
tumour cells. 
Bone metastasis has increased water content and therefore 
appear as hyperintense on T2 Weighted images. On giving 
gadolinium contrast, there is enhancement due to increased 
vascularity.  A compromised oedematous spinal cord will 
demonstrate abnormal focal high T2 and turbo-short tau inversion 
recovery (STIR) signal which can differentiate pathological 
vertebral body fracture from cord compression. Fast pulse 
sequence is a newer MRI technique to acquire whole body 
imaging rapidly over multiple anatomic locations. 
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ADVANTAGES OF MRI: 
 Easy to perform whole body scans 
 No ionizing radiations 
 Can differentiate malignant deposits from osteoporotic 
lesions 
 Assess treatment response on repeat scans applying the 
quantitative  
DIFFUSION WEIGHTED IMAGING(DWI). 
 Additional tumors in the index breast (multifocal or 
multicentric disease) 
 Selecting patients for partial breast irradiation techniques 
 Screening breasts of high-risk young females 
 
DISADVANTAGES: 
 High cost 
 Availability and accessibility 
 Less information on cortical bones compared to CT 
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MRI T1 T2 
GADOLINIUM 
CONTRAST 
NORMAL hyperintense hypointense Non enhanced 
METASTASIS hypointense hyperintense enhances 
 
 
 
FIG: subtle sclerotic changes in T12,L1 on plain film; MRI 
shows metastatic deposits not visible in plain film 
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TECHNIQUES OF MRI 
Breast MRI studies should be performed on 1.5T magnets 
or higher. The high field strength allows for rapid acquisition with 
high-resolution imaging. There is a linear relationship between 
magnetic field strength and signal-to-noise ratio (SNR). With 
greater field strength, the SNR is higher, and higher spatial 
resolution images can be obtained with shorter acquisition times. 
The high field strength also makes homogeneous fat suppression 
possible enabling detection of subtle enhancing lesions. Although 
1.5T magnets remain the standard in breast MRI imaging, 3T 
magnets are commercially available. The higher field strength 
allows for higher SNR, with more rapid imaging speed and 
resolution. However, there is no definitive evidence that 3T 
magnets are superior to 1.5T for clinical breast imaging. 
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FAT SUPPRESSION 
On MRI an enhancing lesion maybe difficult to detect in a 
background of fat. Therefore, fat suppression will improve the 
conspicuity of small enhancing lesions. This can be accomplished 
with either active or passive fat suppression. Using “active” fat 
suppression where the signal from fat is removed prior to the 
injection of intravenous contrast. There are a variety of available 
fat suppression techniques. Alternatively, passive fat suppression 
can be accomplishing with post processing image subtraction 
(subtracting the precontrast from the postcontrast image). This 
requires that there be no patient motion between the pre- and the 
postcontrast sequences. Both methods of fat suppression 
(chemical fat suppression and image postprocessing image 
subtraction) can be used together. 
 
TEMPORAL AND SPATIAL RESOLUTION: 
Sensitivity for the detection of small enhancing foci 
improves with increasing spatial resolution, but this requires 
longer imaging times. The high temporal resolution needed for 
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dynamic contrast enhancement is obtained at the cost of a loss of 
spatial resolution, signal to noise, and/or volume of the breast 
imaged. For optimal spatial resolution, a pixel size of less than 
1.0 mm in each in-plane direction is necessary with 3-mm or less 
slice thickness.  
For optimal temporal resolution, the first post contrast 
images should be obtained in less than 2 minutes following 
contrast injection, with subsequent scans obtained over the 
following 5 to 7 minutes to evaluate the shape of the enhancement 
curve. Different methods may be utilized to optimize these two 
competing factors. One is using a higher field strength magnet. 
3T magnets are available for commercial use.  
Theoretically, compared to 1.5T magnet, a 3T magnet 
should provide double the SNR and therefore allowing for faster 
image acquisition. However, there is no conclusive clinical 
evidence that 3T is superior to 1.5T in terms of diagnostic 
performance. Image acquisition time may also be reduced while 
preserving spatial resolution by using parallel imaging. Parallel 
imaging allows for simultaneous acquisition of spatial 
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information from both coils, thus reducing the time to acquire the 
spatial information. Combination of imaging methods may be 
used as well. Parallel imaging techniques may be further 
optimized on a 3T magnet. 
 
DIFFUSION WEIGHTED IMAGING 
Diffusion-weighted imaging (DWI) may be used to increase 
the specificity of MRI. Although DWI should not be the primary 
method used for lesion analysis, it can be helpful when the other 
imaging parameters such as lesion morphology and kinetic 
information are equivocal. The concept of diffusion is based on 
random and thermal motion of water in tissue, also known as 
Brownian motion. Tissues with high cellularity restrict the 
motion of water whereas tissues with low cellularity allow for 
more free movement of the water molecules. Tumors tend to have 
higher cellularity and hence have restricted motion. On DWI, the 
restricted motion results in a higher signal intensity. The 
technique that is most commonly used to generate DWI imaging 
is T2-weighted echo planar imaging. Due to the higher cellularity 
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of carcinomas, there is restricted diffusion in invasive cancers 
relative to benign lesions and normal parenchyma, resulting in 
relatively brightness of malignant lesions compared to benign 
lesions. 
The most common benign lesions of the vertebra which 
MRI can accurately identify are as follows: 
 
Osteoblastoma of spine: 
Osteoblastoma is a benign bone forming tumour. 
Osteoblastomas tend to be larger in size (>2 cm), often present with 
cortical breakthrough and a soft tissue mass, and may rarely undergo 
malignant transformation. Spinal osteoblastomas account for 30–40% 
of all osteoblastomas. Osteoblastoma originates in the neural arch and 
then extends to the vertebral body. Thoracic, cervical, and lumbar 
segments are equally affected. The most common symptom is pain. 
Radiological presentation of osteoblastoma may vary. Osteoblastoma 
may be similar to osteoid osteomas, with a radiolucent nidus and 
surrounding sclerotic changes. The aggressive variant radiographs 
may show bone expansion with matrix calcifications, cortical bone 
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destruction, paravertebral and epidural extension. MRI is the most 
useful technique for evaluation of the potential mass effect of the 
tumor on neural elements. The imaging characteristics on MRI are  on 
T1-Weighted image, the lesion is hypointense with mixed signal on 
T2-Weighted Image and an intense enhancement. 
 
Hemangiomas of vertebra: 
Vertebral hemangiomas are the most common benign tumors in 
the spine, accounting for 2% of skeletal benign tumors. Vertebral 
hemangiomas are most frequently in the thoracic spine, followed by 
the lumbar region, and rarely in the cervical and sacral segments. 
On radiographs, hemangiomas cause rarefaction of the trabeculae 
which may be thickened causing vertical striation. On CT, these 
vertical striations interspersed with fatty attenuation cause the so-
called polka dot on axial images or corduroy appearance on coronal or 
sagittal reformatted images respectively. On MRI, fatty hemangiomas 
represent inactive forms. Low T1 signal intensity indicates a more 
active lesion with the potential to compress the spinal cord. 
Haemangiomas show avid enhancement. Aggressive hemangiomas 
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involve the entire vertebral body with extension to the neural arch, 
cortical expansion, irregular honeycombing, soft tissue mass and 
contrast enhancement 
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OSTEOPOROSIS 
Osteoporosis is a metabolic skeletal disease defined as a 
reduction of bone mineral density below a defined lower limit of 
normal. 
On MRI, Bone marrow signal takes on a assorted appearance with 
rounded focal fatty lesions replacing normal marrow with 
coalescence often occurring 5: 
 T1: heterogeneously hyperintense 
 T2: variable signal 
Therefore MRI can efficiently distinguish benign and metastatic 
disease as described above. There are several other benign lesions 
of the spine all of which can be identified by characteristic MRI 
appearance. 
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NUCLEAR SCANS: 
The concept of nuclear medicine lies in the quantitative 
functioning of the tumour cells or bone without any anatomy 
details though some scans like PET can be combined with CT for 
structural details. So, the radiotracers used in bone scans deposits 
wherever there is increased bone activity irrespective of the 
etiology-benign or malignant. 
The various agents used as tracers are: 
1. Osteotropic agents like technetium 99, 18NaF(sodium 
fluoride). 
2. 99mTc-MDP(methylene diphosphanate) 
3. Oncotropic radio isotopes like iodine 123 or iodine 131 
4. Indium 111(somatostatin receptor scintigraphy) 
5. Gallium 68 
Despite the high sensitivity they are not specific for metastasis.  
BONE SCINTIGRAPHY: 
 Skeletal scintigraphy is the widely agreed technique for 
metastatic spine deposits. The radionuclide uptake depends upon 
multiple factors like blood flow, the activity of the bone-clastic 
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or blastic and extraction efficiency. The sensitivity and specificity 
are 78% and 48% respectively. 
 
ADVANTAGES: 
 Whole body survey facilitates metastasis detection in the 
entire skeleton 
 High sensitivity 
 0nly 5-10% alteration in bone structure is needed to detect 
lesions hence can detect lesions 18 months earlier than x-
ray. 
 
DISADVANTAGES: 
 Assesses osteoblastic activity only. Hence tumour seedling 
without bone activity are missed. 
 High false positivity rate (non specific) 
 Poor spatial resolution 
 Needs another diagnostic modality to correlate and confirm 
diagnosis. 
 No anatomic details 
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FIG: A bone scintigraphy 
Diagnostic modality of choice: 
As we have discussed above, there is no single investigation 
modality of choice to detect occult spine metastasis in breast 
cancer patients. However depending upon the various factors as 
mentioned there can be predilection towards CT, MRI and bone 
scan.  
WHY WE COMPARED CT AND MRI? 
We selected CT and MRI based upon the concept of recent 
technical advances in MRI which includes but not limited to 
STIR, FLAIR etc., 
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The low specificity of scintigraphy and other disadvantages as 
mentioned made us reconsider the diagnostic modality of choice. 
As medical advances are evolving, the ‘choice’ factors should be 
evaluated time to time.  
Cost & availability factors were also taken into 
consideration. Patients presenting to our institution are far from 
affordable for  PET-CT/SPECT and bone scan. Asymptomatic 
patients were investigated with x-ray skeletal survey and CT if 
suspicious. But as CT may fail to reveal metastasis, we have 
compared MRI and CT scan- the two modalities available and 
feasible in our institution. 
Again, we selected patients with LABC owing to the 
significant incidence of occult metastasis in these patients 
compared to other stages. For obvious reasons stage 4 disease was 
omitted from the study. 
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RESEARCH PROPOSAL 
TITLE  :  Prospective study comparing the effectiveness 
of CT and MRI spine in detecting occult metastasis in patients 
with locally advanced breast carcinoma 
AIMS & OBJECTIVES: To ascertain the best imaging 
modality to detect occult spine metastasis in LABC patients 
therefore ensuring early metastasis diagnosis and appropriate 
management. 
DESIGN OF STUDY: PROSPECTIVE STUDY 
PERIOD OF STUDY: 1 YEAR 
COLLABORATING DEPARTMENT: RADIOLOGY 
SELECTION OF STUDY SUBJECTS: Patients attending 
surgical OPD in our hospital who satisfy the study criteria and 
consent to the study. 
DATA COLLECTION: History, Clinical examination and 
investigations including radiology reports and biopsy reports. 
ETHICAL CLEARANCE: OBTAINED  
CONSENT: Individual written and informed consent 
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CONFLICT OF INTEREST: NONE 
FINANCIAL SUPPORT: NIL FROM THE INSTITUITION 
PARTICIPANTS: Patients from surgical OPD /wards, who 
consent to the study. 
 
INCLUSION CRITERIA: 
1. Patients presenting with stage III carcinoma breast to 
surgical OPD in GRH Madurai. 
2. Patients consented for inclusion in the study according to 
designated proforma 
3. No clinical evidence of metastasis 
 
EXCLUSION CRITERIA: 
1. Patients presenting with early breast carcinoma 
2. Patients presenting with evident metastasis (Stage IV). 
3. Prior chemotherapy/Radiotherapy during first 
presentation 
4. Patients Unwilling for the study. 
5. Pregnant patients 
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METHODOLOGY 
The patients presenting with carcinoma breast in GRH 
Madurai will be recruited for this study.  Following consent, a 
questionnaire will be filled to record the patient's demographic 
data, duration of disease, symptoms, & treatment history. After 
diagnosis and study criteria confirmation, patients will undergo 
CT Spine and MRI Spine. 
 
DATA ANALYSIS: 
Chi square test – p value (<0.05 IS TAKEN SIGNIICANT) 
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PROTOCOL 
 
 
 
 
Patients with 
LABC
X-RAY SKELETAL 
SURVEY
CT SPINE
MRI SPINE
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INCLUSION 
CRITERIA 
EXCLUSON CRITERIA 
 Patients 
present with 
stage III 
carcinoma 
breast 
 Patients 
consented for 
the study 
 No clinical 
evidence of 
metastasis 
 
 Patients presenting with 
early breast carcinoma 
 Patients presenting with 
evident metastasis (Stage 
IV). 
 Prior 
chemotherapy/Radiotherapy 
during first presentation 
 Patients Unwilling for the 
study. 
 Pregnant patients 
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DATA FORM 
NAME:      AGE/SEX:  
 IP: 
FNAC:           
TRUCUT:         
DIAGNOSIS:       T        N        M 
CO MORBIDITIES: 
CHRONIC DRUG INTAKE: 
BONE PAIN/FRACTURES: 
RECENT BONE PAIN: 
DURATION OF BREAST DISEASE:    
 NODES: 
MAMMOGRAM: 
 
U/S BREAST: 
 
U/S ABDOMEN: 
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TOTAL BILI  
mg% 
 SGPT  
U/L 
 ALP  U/L  
DIRECT BILI 
mg% 
 SGOT  
U/L 
 S. calcium 
mg% 
 
 
PRIOR CHEMOTHERAPY: 
PRIOR RADIOTHERAPY: 
 
X-RAY FINDINGS: 
 CHEST: 
 
 CERVICAL SPINE: 
 
 THORACIC SPINE: 
 
 LUMBPSACRAL SPINE: 
 
 PELVIS: 
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 SKULL: 
 
MRI FINDINGS: 
 SPINE: 
 
 
CT FINDINGS: 
DL SPINE: 
 
SACRAL AND CERVICAL SPINE: 
 
REMARKS:  
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OBSERVATION AND RESULTS: 
 64 patients were subjected to the study. All patients underwent 
both MRI and CT spine. The age distribution is as follows. 
 
 
 
 
Out of the 64 patients most common age group was <56 years.  
AGE No of pts % 
<45 22 34.38 
46 - 55 28 43.75 
56 - 65 10 15.63 
>65 4 6.25 
TOTAL 64 100.00 
0
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No of pts
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Right sided predominance was seen among our patients keeping 
in line with the global cues. 
SIDE No of Cases % 
LEFT 26 40.63 
RIGHT 38 59.38 
TOTAL 64 100.00 
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The mean duration of presentation of our patients was 2.5 
months(0.5-5 months). Hence the patients were categorized 
accordingly with predominant patients presenting in less than 2.5 
months duration.   
DURATION OF 
DISEASE (MONTHS) 
No of Cases % 
< 2.5 48 75.00 
>2.5 16 25.00 
TOTAL 64 100.00 
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16
64
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< 2.5 >2.5 TOTAL
69 
 
 
 
As high as 40 patients out of 64 presented with lump in the upper 
and outer quadrant, the most common quadrant for carcinoma. 
The upper quadrant tops overall.  
 
QUADRANT NO OF PTS % 
LOWER OUTER 2 3.13 
UPPER INNER 8 12.50 
UPPER OUTER 40 62.50 
UPPER 14 21.88 
TOTAL 64 100.00 
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The mean lump size was 5cms (4-8cms).  
 
LUMP SIZE (CM) No of Cases % 
4 20 31.25 
5 28 43.75 
6 10 15.63 
7 4 6.25 
8 2 3.13 
TOTAL 64 100.00 
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80% patients presented with nodes 3 or less. Almost all patients 
had clinically palpable nodes. 
NODES No of Cases % 
1 18 28.13 
2 22 34.38 
3 14 21.88 
4 4 6.25 
5 6 9.38 
TOTAL 64 100.00 
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Metastasis was most common in age 46-55yrs. All patients above 
65 years had metastasis.  
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Almost all the patients with metastasis had their primary lump in 
the upper quadrant except 1 patient who had in lower quadrant.  
P value=0.023 
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Bone pain was present in only 2 patients whereas 62 patients were 
asymptomatic at presentation  
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CT identified metastasis in two patients whereas MRI identified 
metastasis in 11 patients. The p value is 0.038 (significant).  
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The duration of disease presentation correlated with MRI findings 
in which 9 patients who had duration of disease more than 2.5 
months from presentation had metastasis compared to only 2 
patients in the other category. p value is 0.042 (significant). 
 
 
 
 
2
9
DURATION OF DISEASE VS MRI FINDINGS
p value: 0.042
<2.5months =2
>2.5months = 9
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DISCUSSION 
In our study, MRI was significant in detecting occult spine 
metastasis compared to plain CT spine.   
All patients above the age of 65 had metastasis. However 
this is statistically insignificant (p value = 0.72). The second most 
common age in which metastasis was detected was 46-55years. 
All The patients with spine metastasis had their primary 
lump in the upper quadrant which is significant (p value =0.001) 
The lump size had an influence in the metastatic deposits as 
most patients with spine metastasis had a lump size of >5cms. 
This was also statistically significant with a p value of 0.03 
X-Ray skeletal survey failed to detect any patient with 
metastasis whereas CT detected 2 patients with metastasis. 
MRI detected metastasis in 11 patients including the 2 detected 
by CT. (p value=0.038) 
 The co morbidities like diabetes and hypertension does not 
seem to play a role in metastasis. The number of nodes and 
metastasis showed a wide variation with no specific relation to 
metastasis.  
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CONCLUSION 
 
We conclude that MRI of spine is at present the practically 
best modality of choice in patients with locally advanced breast 
carcinoma to detect occult metastasis. Hence MRI spine should 
be incorporated and preferred over CT spine for metastatic work 
up of patients. Early detection of such occult metastasis can 
change the patients disease stageing altogether thereby 
influencing the management modality. With the rapid 
advancement in medical technologies MRI  may further improve 
in its quality and can emerge as the investigation of choice for 
spine metastasis.  
 
Limitations of the Study: 
The sample size is small. Due to non availability, bone scan 
couldn’t be used to compare MRI findings. 
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MASTER CHART 
 
S.N
o. 
NAME AGE SEX Right/Left TYPE DURATION OF 
DISEASE 
(MONTHS) 
QUADRANT  LUMP 
SIZE 
(CM) 
NODES BONE 
PAIN 
STAGE XRAY CT DL 
SPINE 
MRI DL 
SPINE 
DM HTN 
1 SUBATHRADEVI 51 F LEFT IDC 2 UO 5*3 2 NO III NO NO NO NO NO 
2 RAJAMANI 70 F LEFT IDC 3.5 UO 4*4 3 YES III NO NO YES;  YES NO 
3 POTHUM PONNU 40 F RIGHT IDC 2 UO 5*4 3 NO III NO NO NO NO NO 
4 RAMU 36 F RIGHT IDC 2 UI 5*4 5 NO III NO NO NO NO NO 
5 SHANTHA 75 F LEFT IDC 4 UO 7*5 1 YES III NO NO YES;  NO NO 
6 JOTHILAKSHMI 43 F LEFT IDC 1 UO 5*4 2 NO III NO NO NO YES YES 
7 NAGARAMMAL 43 F RIGHT IDC 2 UO/UI 5*3 1 NO III NO NO NO NO NO 
8 VASANTHA 51 F RIGHT IDC 2.5 UO/UI 5*5 3 NO III NO NO YES;  NO YES 
9 PAPPATHI 49 F RIGHT IDC 2.5 UI 4*5 2 NO III NO NO NO NO NO 
10 KARUPAYEE 45 F RIGHT IDC 2 UO 6*5 3 NO III NO NO NO NO NO 
11 VEERAMMAL 40 F LEFT IDC 1.5 UI 5*4 2 NO III NO NO NO NO NO 
12 SOORAYEE 42 F RIGHT IDC 0.5 UO 5*3 4 NO III NO NO NO YES YES 
13 PREMA 60 F RIGHT IDC 3 UO/UI 5*4 3 NO III NO NO NO NO NO 
14 SUDHA 42 F LEFT IDC 1 UO 4*3 2 NO III NO NO NO NO NO 
15 KURUVAMMAL 50 F LEFT IDC 1.5 UO/UI 4*3 2 NO III NO NO NO NO NO 
16 MADATHIYAMMAL 53 F LEFT IDC 2 UO/UI 6*5 1 NO III NO NO NO NO NO 
17 VASANTHA 47 F RIGHT IDC 1 LO 4*5 2 NO III NO NO NO NO NO 
18 SANTHANA MARY 49 F LEFT IDC 0.5 UO 4*4 1 NO III NO NO NO NO NO 
19 NAJEEMA 43 F RIGHT IDC 1 UO 6*6 2 NO III NO NO NO NO NO 
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20 SELVI 49 F RIGHT IDC 4 UO/UI 7*5 2 NO III NO NO NO NO NO 
21 RAKKU 60 F RIGHT IDC 3.5 UO 4*5 1 YES III NO NO YES;  YES NO 
22 MEENA 52 F RIGHT IDC 1.5 UO 5*5 2 NO III NO NO NO NO NO 
23 LAKSHMI 56 F LEFT IDC 2 UI 4*6 3 NO III NO NO NO NO NO 
24 BAKIYAM 48 F RIGHT IDC 1 UO 5*3 1 NO III NO NO NO NO NO 
25 ALAGAMMAL 48 F RIGHT IDC 1 UO 6*4 5 NO III NO NO NO NO NO 
26 MUTHULAKSMI 53 F LEFT IDC 0.5 uo 5*5 1 NO III NO NO NO NO NO 
27 petchiammal 40 F RIGHT IDC 2 UO 4*6 3 NO III NO NO NO NO NO 
28 TAMILARASI 55 F LEFT IDC 4 UO 6*8 4 NO III NO NO NO NO NO 
29 DHANAM 44 F RIGHT IDC 3 UO 5*4 1 YES III NO NO YES;  NO NO 
30 PONNIAMMAL 65 F RIGHT IDC 2 UO 4*5 1 YES III NO NO NO NO NO 
31 NAGAJOTHI 47 F LEFT IDC 1 UO 5*6 2 YES III NO NO YES;  NO NO 
32 CHELLAYEE 58 F RIGHT IDC 5 UO/UI 8*7 5 NO III NO NO NO NO NO 
33 SIGAPPI 60 F RIGHT IDC 3.5 UO 4*5 1 YES III NO NO YES;  NO NO 
34 OCHAMMAL 52 F RIGHT IDC 1.5 UO 5*5 2 NO III NO NO NO NO NO 
35 SARASWATHI 56 F LEFT IDC 2 UI 4*6 3 NO III NO NO NO NO NO 
36 PALANI MUTHU 48 F RIGHT IDC 1 UO 5*3 1 NO III NO NO NO NO NO 
37 AYESHA BEEVI 45 F RIGHT IDC 2 UO 6*5 3 NO III NO NO NO NO NO 
38 OKKICHI 40 F LEFT IDC 1.5 UI 5*4 2 NO III NO NO NO NO NO 
39 PACHIAMMAL 42 F RIGHT IDC 0.5 UO 5*3 4 NO III NO NO NO NO NO 
40 ARASAMMAI 60 F RIGHT IDC 3 UO/UI 5*4 3 NO III NO NO NO NO NO 
41 UMAYAL 42 F LEFT IDC 1 UO 4*3 2 NO III NO NO NO NO NO 
42 RANGANAYAKI 50 F LEFT IDC 1.5 UO/UI 4*3 2 NO III NO NO NO NO NO 
43 FATHIMA 48 F RIGHT IDC 1 UO 6*4 5 NO III NO NO NO NO NO 
44 PATTU 53 F LEFT IDC 0.5 uo 5*5 1 NO III NO NO NO NO NO 
45 ALAGU 40 F RIGHT IDC 2 UO 4*6 3 NO III NO NO NO NO YES 
46 PONNAMMAL 55 F LEFT IDC 4 UO 6*8 4 NO III NO NO NO NO NO 
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47 DHANAM 51 F LEFT IDC 2 UO 5*3 2 NO III NO NO NO NO NO 
48 POTHUMPONNU 70 F LEFT IDC 3.5 UO 4*4 3 YES III NO NO YES;  NO NO 
49 PECHIAMMAL 40 F RIGHT IDC 2 UO 5*4 3 NO III NO NO NO NO NO 
50 PACKIALAXMI 36 F RIGHT IDC 2 UI 5*4 5 NO III NO NO NO NO NO 
51 KANAGAMMAL 53 F LEFT IDC 2 UO/UI 6*5 1 NO III NO NO NO NO NO 
52 LAKSHMI 47 F RIGHT IDC 1 LO 4*5 2 NO III NO NO NO NO NO 
53 THOTICHI 49 F LEFT IDC 0.5 UO 4*4 1 NO III NO NO NO NO NO 
54 PANGAJAM 43 F RIGHT IDC 1 UO 6*6 2 NO III NO NO NO NO NO 
55 RASATHI 49 F RIGHT IDC 4 UO/UI 7*5 2 NO III NO NO NO NO YES 
56 MUNIAMMAL 44 F RIGHT IDC 3 UO 5*4 1 YES III NO NO YES;  NO NO 
57 CHELLAM 65 F RIGHT IDC 2 UO 4*5 1 YES III NO NO NO NO NO 
58 JEGADHEESWARI 47 F LEFT IDC 1 UO 5*6 2 YES III NO NO YES;  NO NO 
59 
AMALORPAVA 
MARY 58 F RIGHT IDC 5 UO/UI 8*7 5 NO III NO NO NO NO NO 
0 ANJALAI 75 F LEFT IDC 4 UO 7*5 1 YES III NO NO YES;  NO NO 
61 BARGATH NISHA 43 F LEFT IDC 1 UO 5*4 2 NO III NO NO NO NO NO 
62 RUKKU 43 F RIGHT IDC 2 UO/UI 5*3 1 NO III NO NO NO NO NO 
63 CHINNIAMMAL 51 F RIGHT IDC 2.5 UO/UI 5*5 3 NO III NO NO YES;  YES NO 
64 VEERAYEE 49 F RIGHT IDC 2.5 UI 4*5 2 NO III NO NO NO NO NO 
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